{"id":11296,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T17:06:05","modified_gmt":"2025-10-03T17:06:05","slug":"hupertermia-vahiga-patsientide-elulemus","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/et\/hupertermia-vahiga-patsientide-elulemus\/","title":{"rendered":"H\u00fcpertermia ja v\u00e4higa patsientide elulemus: Kliinilised t\u00f5endid n\u00e4itavad \u00fcldise elulemuse (OS) kasvu \u00fcle 50%"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"H\u00fcpertermia ja v\u00e4higa patsientide elulemus: Kliinilised t\u00f5endid n\u00e4itavad \u00fcldise elulemuse (OS) kasvu \u00fcle 50%\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"H\u00fcpertermia, Onkoloogia, III faasi uuringud, elulemus, OS, T\u00e4ielik vastus, CR, Glioblastoom, k\u00f5hun\u00e4\u00e4rmev\u00e4hk, Sarkoom, emakakaelav\u00e4hk, rinnav\u00e4hk, E-E-A-T\"\n      \/* ... Schema FAQPage lisatakse eraldi Korduma Kippuvate K\u00fcsimuste jaotise jaoks *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoriteet ja asjatundlikkus (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00e4lja t\u00f6\u00f6tanud <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/et\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan, MD, ja <\/span><\/span><\/a><a href=\"https:\/\/andromedichyperthermia.com\/et\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">H\u00fcpertermia ja v\u00e4higa patsientide elulemus: Kliinilised t\u00f5endid n\u00e4itavad \u00fcldise elulemuse (OS) kasvu \u00fcle 50% teatud juhtudel<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00e4hivastases v\u00f5itluses on \u00fclim eesm\u00e4rk <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00fcldise elulemuse (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">pikendamine minimaalse v\u00f5i olematu lisatoksilisusega. T\u00e4nu oma ainulaadsele v\u00f5imele muuta v\u00e4hirakud kiiritusravi ja keemiaravi suhtes tundlikumaks, on <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">h\u00fcpertermia (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> selle eesm\u00e4rgi \u00fcletanud. <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/oncologic-hyperthermia-phase-3-trials\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomiseeritud III faasi kliiniliste uuringute (RCT-de) ja meta-anal\u00fc\u00fcside<\/span><\/span><\/strong> <span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> andmed n\u00e4itavad, et h\u00fcpertermia lisamine standardprotokollidele v\u00f5ib agressiivsete kartsinoomide puhul suurendada <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*\u00fcldist elulemust 20%, 50% ja isegi \u00fcle 100% **<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Esitame k\u00f5ige veenvamad t\u00f5endid koos otselinkidega algsetele publikatsioonidele:<\/span><\/span><\/a><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. 2-aasta elulemuse kahekordistamine: Glioblastoma Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblastoma Multiforme (GBM) on k\u00f5ige agressiivsem ajukasvaja <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomiseeritud I\/II faasi kliiniline uuring<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] n\u00e4itas, et h\u00fcpertermia lisamine brahh\u00fcteraapiale p\u00e4rast tavap\u00e4rast kiiritusravi avaldas dramaatilist m\u00f5ju v\u00e4higa patsientide prognoosile, konkreetselt <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">kahekordistades 2-aasta elulemuse m\u00e4\u00e4ra<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkoloogiline n\u00e4itaja<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standardravi (ilma HT-ta)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Standard + h\u00fcpertermia (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Suhteline m\u00f5ju (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Elulemus \u2013 2 aastat<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%15<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%31<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">OS suhteline kasv +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00e4higa patsientide elulemuse suhteline kasv \u00fcle 100% 2 aasta jooksul on kaalukas t\u00f5estus h\u00fcpertermia kui t\u00e4iendava v\u00e4hiravi t\u00f5hususest.<\/span><\/span><\/strong><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hiljutisemad meta-anal\u00fc\u00fcsid [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> kinnitavad moduleeritud RF-h\u00fcpertermia (mHT) sarnaseid eeliseid \u00e4sja diagnoositud haiguse korral, n\u00e4idates <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1-aasta elulemuse m\u00e4\u00e4ra 73% v\u00f5rreldes 37% kontrollr\u00fchmas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (korduv haigus) (p = 0.0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00f5rdlevatest uuringutest saadud tugevad elulemuse signaalid, isegi glioomide keerulises kliinilises keskkonnas, \u00f5igustavad HT lisamist kliinilistesse suunistesse 1A taseme n\u00e4idustusena.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Pikenenud elulemus: K\u00f5hun\u00e4\u00e4rmev\u00e4hi korral \u00fcle 50% OS kasv<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u00f5hun\u00e4\u00e4rme kartsinoom (PC) on \u00fcks halvema prognoosiga v\u00e4hke. Konsolideeritud kliinilised t\u00f5endid n\u00e4itavad, et h\u00fcpertermia muudab kliinilist kulgu oluliselt, demonstreerides j\u00e4rjepidevalt \u00fcle 50% OS kasvu v\u00e4higa patsientidel:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HEAT adjuvantne randomiseeritud kliiniline uuring (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Resekteeritava k\u00f5hun\u00e4\u00e4rme adenokartsinoomi korral t\u00f5i piirkondliku h\u00fcpertermia (RHT) lisamine kaasa <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-aasta elulemuse m\u00e4\u00e4rad 28.4% versus 18.7%\\* ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*52% suhteline elulemuse kasv<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integreeritud v\u00f5rdlev uuring (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Metastaatilise k\u00f5hun\u00e4\u00e4rmev\u00e4hi korral leiti, et integreeritud immunomoduleeriv ravi (kaasa arvatud moduleeritud RF-h\u00fcpertermia, mHT) oli tavap\u00e4rasest keemiaravist m\u00e4rkimisv\u00e4\u00e4rselt parem.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"K\u00f5hun\u00e4\u00e4rmev\u00e4hk \u2013 \u00fcldine elulemus OS \u2013 immunomoduleerivate ravimeetodite (IMT) VS keemiaravi (CT) VS moduleeritud RF-h\u00fcpertermia (mHT) + CT v\u00f5rdlus\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u00f5hun\u00e4\u00e4rmev\u00e4hk \u2013 \u00fcldine elulemus OS \u2013 immunomoduleerivate ravimeetodite (IMT) VS keemiaravi (CT) VS moduleeritud RF-h\u00fcpertermia (mHT) + CT v\u00f5rdlus<\/span><\/span><\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Suur mitmekeskuseline retrospektiivne vaatlusuuring<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih-gov\/37398545\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 III-IV staadiumi PC patsienti) v\u00f5rdles moduleeritud RF-h\u00fcpertermiat (mHT) + CT (enamasti gemsitabiinil p\u00f5hinev) ainult CT-ga. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf \u00dcldine elulemus (OS): OS paranes moduleeritud RF-h\u00fcpertermia (mHT) r\u00fchmas oluliselt (rohkem kui KAHEKORDSELT) (20 kuud, v\u00f5rreldes 9 kuuga ainult CT r\u00fchmas, P &lt; 0.001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Progressioonivaba elulemus (PFS): PFS paranes samuti oluliselt (7 kuud, v\u00f5rreldes 5 kuuga, P &lt; 0.05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Kasvaja vastus: Kohaliku RF-h\u00fcpertermia (mHT) saanud patsientidel oli oluliselt k\u00f5rgem osalise vastuse (PR) m\u00e4\u00e4r (45% versus 24%, P = 0.0018) ja oluliselt madalam progressioonim\u00e4\u00e4r (PD) (4% versus 31%, P &lt; 0.01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Pikaajaline III faasi dokumentatsioon: Pehmete kudede sarkoom (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomiseeritud, rahvusvahelises III faasi kliinilises uuringus (RCT), mis on kuldstandard,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">NACT-i (neoadjuvantne keemiaravi) saanud pehmete kudede sarkoomi (STS) patsientidel <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">rohkem kui kahekordistus mediaan \u00fcldine elulemus (OS)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, minimaalse toksilisusega, mis viis HT lisamiseni NCCN ja ESMO suunistesse.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Uuringu algatas <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Euroopa H\u00fcpertermilise Onkoloogia Selts (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ja seda koordineeris Saksamaal asuv Klinikum der Universit\u00e4t M\u00fcnchen koost\u00f6\u00f6s Euroopa V\u00e4hiuuringute ja -ravi Organisatsiooni (EORTC) pehmete kudede ja luu sarkoomi r\u00fchmaga (STBSG). Osalevad akadeemilised keskused asusid Saksamaal (6), Norras (1), Austrias (1) ja USA-s (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ajavahemikul juulist 1997 kuni novembrini 2006 registreeriti 9 keskuses t\u00e4iskasvanud patsiendid (vanus \u226518 aastat) lokaliseeritud pehmete kudede sarkoomiga (kasvaja \u22655 cm, aste 2 v\u00f5i 3, s\u00fcgav, vastavalt Prantsuse V\u00e4hivastaste Keskuste Riikliku F\u00f6deratsiooni [FNCLCC] klassifikatsioonile). J\u00e4relkontroll l\u00f5ppes detsembris 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Piirkondliku h\u00fcpertermia (RHT) lisamine pikendas mediaan haigusvaba elulemust 17.4 kuult 33.3 kuuni<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR lokaalse v\u00f5i kaugemal asuva eba\u00f5nnestumise v\u00f5i surma korral, 0.71; 95% CI, 0.55\u20130.93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0.01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Joonis 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Elulemus paranes uuringur\u00fchmade vahel oluliselt NACT pluss RHT r\u00fchmas, mille mediaan pikkus oli 15.4 aastat, v\u00f5rreldes ainult NACT r\u00fchma 6.2 aastaga<\/strong> (HR 0.73; 95% CI, 0.54-0.98;\u00a0<i>P<\/i>\u2009=\u20090.04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Joonis 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>5- ja 10-aasta elulemuse m\u00e4\u00e4rad olid NACT pluss RHT r\u00fchmas vastavalt 62.7% (95% CI, 55.2%-70.1%) ja 52.6% (95% CI, 44.7%-60.6%)<\/strong> ning ainult NACT r\u00fchmas vastavalt 51.3% (95% CI, 43.7%-59.0%) ja 42.7% (95% CI, 35.0%-50.4%). Elulemuse kasu saamiseks 5 ja 10 aasta jooksul vajalike patsientide arv oli vastavalt 8.8 ja 10.1. Post-hoc anal\u00fc\u00fcsid n\u00e4itasid, et j\u00e4semetega seotud kasvajatega patsientidel olid RHT kasuks 5- ja 10-aasta elulemuse m\u00e4\u00e4rad 75.2% versus 60.8% (absoluutne erinevus, 14.4%; 95% CI, 0.0%-29.5%) ja 68.3% versus 59.2% (absoluutne erinevus, 9.1%; 95% CI, 0%-24.7%). Mitte-j\u00e4semetega seotud kasvajatega patsientidel olid RHT kasuks 5- ja 10-aasta elulemuse m\u00e4\u00e4rad 53.5% versus 44% (absoluutne erinevus, 9.5%; 95% CI, 0%-23.8%) ja 41.3% versus 29.9% (absoluutne erinevus, 11.4%; 95% CI 0%-25.1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Joonis 2<\/a>D). Ravivastuste kokkuv\u00f5te on esitatud\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Lisa 2<\/a> tabelis e1.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Piirkondliku h\u00fcpertermia lisamine neoadjuvantsele keemiaravile parandas elulemust oluliselt, absoluutne erinevus oli 5 aasta jooksul 11.4% ja 10 aasta jooksul 9.9%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> v\u00f5rreldes ainult neoadjuvantse keemiaraviga.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. III faasi kliinilistest uuringutest saadud 1A taseme t\u00f5endid: T\u00e4ieliku vastuse (CR) ja elulemuse (OS) paranemine<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Emakakaelav\u00e4hk (12-aasta j\u00e4relkontroll)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Hollandi S\u00fcgavh\u00fcpertermia uuring (III faas), mida uuendati 12 aasta pikkuse j\u00e4relkontrolli j\u00e4rel, n\u00e4itas \u00fcldise elulemuse (OS) suurt paranemist: <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% RT+HT r\u00fchmas versus 20% ainult RT r\u00fchmas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Korduv rinnav\u00e4hk (rindkere sein)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Meta-anal\u00fc\u00fcs<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> n\u00e4itas <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">t\u00e4ieliku vastuse (CR) m\u00e4\u00e4ra suhtelist kasvu +58% HT lisamisega korduvkiiritusele. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kahe haruga uuringutes saavutati <strong>t\u00e4ielik vastus (CR) 60.2% RT + HT korral<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">versus 38.1% ainult RT korral<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(koefitsientide suhe 2.64, 95% usaldusvahemik [CI] 1.66\u20134.18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001). Riskisuhe ja riskide erinevus olid vastavalt 1.57 (95% CI 1.25\u20131.96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0.0001) ja 0.22 (95% CI 0.11\u20130.33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0.0001).<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rektaalv\u00e4hk (edasij\u00f5udnud\/korduv)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-aasta j\u00e4relkontrolli j\u00e4rel olid \u00fcldise elulemuse (OS) m\u00e4\u00e4rad <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95.8 vs 74.5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.045), haigusvaba elulemuse (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89.1 vs 70.4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.027), lokaalse retsidiivivaba elulemuse ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97.7 vs 78.7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.006) ja kolostoomiavaba elulemuse ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87.7 vs 69.0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0.016) puhul h\u00fcpertermia lisamisega ravitud v\u00e4higa patsientide r\u00fchmas oluliselt paremad.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pea- ja kaelav\u00e4hk (HNC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomiseeritud III faasi uuringud<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> n\u00e4itasid 5-aasta OS pidevat kasvu 50%-lt 68.4%-le (p &lt; 0.005). 5-aasta haigusvaba elulemus (DFS) suurenes 25.5%-lt 51.3%-le (p &lt; 0.005). CR m\u00e4\u00e4r kasvas samuti 62.8%-lt 81.6%-le. Teises <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III faasi uuringus[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">t\u00e4heldati t\u00e4ielikku vastust (CR) 42.4 % ainult kiiritusravi r\u00fchmas versus 78.6 % HT r\u00fchmas<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Erinevus oli statistiliselt oluline (&lt; 0.05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u00f5rge riskiga pahaloomuline melanoom (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* \u00dcks <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">II\/III faasi kliiniline uuring[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> n\u00e4itas, et piirkondlik h\u00fcpertermia koos keemiaraviga parandab oluliselt \u00fcldist elulemust isegi kaugelearenenud melanoomiga patsientidel:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-aasta \u00fcldine elulemus:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00dcldine m\u00e4\u00e4r oli 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-aasta elulemus t\u00e4ielikult kontrollitud haigusega patsientidel:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Suurenes <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%-le<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2-aasta aktuaalne lokaalne kontroll <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% VERSUS <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% HT r\u00fchmas <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Oluline paranemine (p = 0.008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kuseteede v\u00e4hk (mittelihasesse infiltreeruv)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Kuseteede v\u00e4hk on \u00fcks 1A taseme n\u00e4idustustest h\u00fcpertermia lisamiseks onkoloogilisele ravile.[12] H\u00fcpertermiline intravesikaalne keemiaravi (HIVEC) koos mitom\u00fctsiin C-ga on v\u00e4ljakujunenud meetod, mis n\u00e4itab retsidiivim\u00e4\u00e4rades olulist paranemist:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Retsidiivi v\u00e4henemine: Mittelihasesse infiltreeruva keskmise ja k\u00f5rge riskiga kuseteede v\u00e4hi korral on HIVEC osutunud paremaks kui standardne toatemperatuuril tehtav keemiaravi infusioon.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsolideeritud tulemused: Meta-anal\u00fc\u00fcsid ja kliinilised uuringud (sh randomiseeritud uuringud) teatasid retsidiiviriskide v\u00e4henemisest \u00fcle 30 % v\u00f5rreldes standardse intravesikaalse keemiaraviga keskmise ja k\u00f5rge riskiga patsientidel [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">T\u00f5husus BCG eba\u00f5nnestumise korral: HIVEC on oluline alternatiiv patsientidele, kellel on standardne BCG (Bacillus Calmette-Gu\u00e9rin) ravi eba\u00f5nnestunud v\u00f5i vastun\u00e4idustatud, parandades retsidiivivaba elulemust (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Ohutus ja soodne terapeutiline indeks (toksilisus)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III faasi dokumentatsiooni oluline aspekt on see, et tohutu elulemuse kasv saavutatakse ilma raske 3. v\u00f5i 4. astme toksilisuse olulise suurenemiseta. N\u00e4iteks emakakaelav\u00e4hi meta-anal\u00fc\u00fcsid ei teatanud olulistest erinevustest \u00e4geda v\u00f5i hilinenud toksilisuse osas (RR 0.99 \u00e4geda toksilisuse korral, RR 1.01 hilinenud toksilisuse korral).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">See t\u00e4helepanek kehtib ka teiste n\u00e4idustuste puhul, tugevdades argumenti, et HT pakub paremat terapeutilist indeksit, v\u00f5imaldades patsientidel paremini taluda keerulisi raviskeeme ja nautida pikemas perspektiivis paremat el Kvaliteeti.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kokkuv\u00f5te: Sertifitseeritud elulemusstrateegia<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Olenemata sellest, kas tegemist on <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">52% OS kasvuga (k\u00f5hun\u00e4\u00e4rmev\u00e4hk), +17 protsendipunkti kasvuga 12 aasta jooksul (emakakaelav\u00e4hk) v\u00f5i Elulemuse kahekordistamisega (glioblastoom ja pehmete kudede sarkoom),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> kinnitab randomiseeritud uuringute dokumentatsioon, et h\u00fcpertermia ei ole lihtsalt t\u00e4iendav ravi, vaid oluline komponent, mis muudab positiivselt v\u00e4higa patsientide <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00fcldise elulemuse<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> kulgu.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kui teie eesm\u00e4rk on maksimeerida \u00fcldist elulemust, on h\u00fcpertermia integreerimine standardprotokolli teaduslikult valideeritud otsus, mille tulemused n\u00e4itavad teatud n\u00e4idustuste puhul suhtelist kasvu \u00fcle 50%.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">E-E-A-T garantii:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> See sisu p\u00f5hineb konsolideeritud andmetel III faasi randomiseeritud kliinilistest uuringutest ja prospektiivsetest randomiseeritud uuringutest, mis on avaldatud tunnustatud meditsiiniajakirjades. T\u00e4ielikud viited on integreeritud linkidega algsetele publikatsioonidele.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Viited:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoriteet ja asjatundlikkus (E-E-A-T): V\u00e4lja t\u00f6\u00f6tanud Dr. Veronica Iatan, MD, ja Cristian Gologan M.Sc, Andromedichyperthermia H\u00fcpertermia ja v\u00e4higa patsientide elulemus: Kliinilised t\u00f5endid n\u00e4itavad \u00fcldise elulemuse (OS) kasvu \u00fcle 50% teatud juhtudel V\u00e4hivastases v\u00f5itluses on \u00fclim eesm\u00e4rk \u00fcldise elulemuse (Overall Survival, OS) pikendamine minimaalse v\u00f5i olematu lisatoksilisusega. T\u00e4nu oma ainulaadsele v\u00f5imele muuta v\u00e4hirakud kiiritusravi ja keemiaravi&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[903,34,108],"tags":[491,406,411,817,132,405,815,404,494,816,410,910,814],"class_list":["post-11296","post","type-post","status-publish","format-standard","hentry","category-studii-clinice-et","category-uncategorized-et","category-uudised","tag-cr-et","tag-elulemus","tag-emakakaelavahk","tag-glioblastoom-et","tag-hupertermia","tag-iii-faasi-uuringud","tag-kohunaarmevahk","tag-onkoloogia","tag-os-et","tag-rinnavahk","tag-sarkoom","tag-studii-faza-iii-et","tag-taielik-vastus"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/11296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/comments?post=11296"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/11296\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media?parent=11296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/categories?post=11296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/tags?post=11296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}